PRTC

PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

Retrieved on: 
목요일, 10월 14, 2021
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PureTech Health, Axis, LSE, Degenerative disease, Immune system, Industry, Private Securities Litigation Reform Act, Cancer, Environment, Massachusetts Bar Association, Doctor of Philosophy, Neurology, Cell Signaling Technology, Biogen, Inflammatory Bowel Diseases, IP, Corporation, Rutgers University, BIG, Economics, SEC, Therapy, Texas Tech University College of Agricultural Sciences & Natural Resources, McDermott Will & Emery, Brain, FDA, Active ingredient, Biology, Cell, Food allergy, Company, University, Annual report, CST, Bacteria, PRTC, Twitter, Biochemistry, Research, Entrepreneurship, U.S. FDA, University of Pennsylvania Law School, Pharmaceutical industry, Public relations

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, announced today that its Founded Entity, Vedanta Biosciences (Vedanta) has appointed Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, announced today that its Founded Entity, Vedanta Biosciences (Vedanta) has appointed Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary.
  • Dr. Levi spent more than 25 years working as legal counsel for corporate and intellectual property matters in the life sciences industry.
  • We are excited to welcome Simona to the Vedanta team and look forward to her contributions.
  • Dr. Levi spent more than 25 years working as legal counsel for corporate and intellectual property matters in the life sciences industry.

PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being

Retrieved on: 
화요일, 10월 5, 2021
Software, Biotechnology, Audio, Video, General Health, Health, Mental Health, Medical Devices, Technology, Cancer, Mental, Human, IOS, Health minister, Axis, Annual report, Therapy, API, Health, Private Securities Litigation Reform Act, Depression, Overalls, FDA, COVID-19, Patient, NCSP, Â, EAPS, Biomarker, Android, PureTech Health, Workplace, Biology, Environment, Twitter, PRTC, Degenerative disease, CEO, Company, LSE, Respiratory disease, U.S. FDA, Awareness, Mental health, Technology, Research, BIG, Brain, Machine learning, Doctor of Philosophy, Time, Anxiety, SEC, Medicine, Pharmaceutical industry, Video game, Mobile phone, Cassette tape, Health insurance, Toy, Sonde Health, PureTech Health, SONDE HEALTH, PURETECH HEALTH

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, today announced that its Founded Entity, Sonde Health (Sonde), has launched Sonde Mental Fitness, a voice-enabled mental health detection and monitoring technology that uses a brief voice sample to evaluate mental well-being.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, today announced that its Founded Entity, Sonde Health (Sonde), has launched Sonde Mental Fitness, a voice-enabled mental health detection and monitoring technology that uses a brief voice sample to evaluate mental well-being.
  • As the strain of the Covid-19 pandemic on mental health continues, Sonde Mental Fitness aims to create awareness among those who may be struggling with mental health issues but may not be receiving treatment.
  • The full text of the announcement from Sonde is as follows:
    BOSTON October 5, 2021 Sonde Health has unveiled Sonde Mental Fitness , a voice-enabled mental health detection and monitoring technology that uses a brief voice sample to evaluate mental well-being.
  • As the pandemics strain on mental health continues, Sonde Mental Fitness aims to shrink that gap by creating awareness.

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Retrieved on: 
화요일, 10월 5, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Mortality, PCR, Medical microbiology, Clinical trial, Assistant, Inflammatory Bowel Diseases, Orphan, Diagnosis, Recurrence, Infection, Therapy, United States Department of Health and Human Services, Doctor of Philosophy, Biomedical Advanced Research and Development Authority, Patient, Death, Population, Feces, BARDA, HHS, Development, MSU MFA Program in Science & Natural History Filmmaking, University, Disease, Odds ratio, Bacteria, Immune system, List of life sciences, Contract manufacturing organization, PRTC, LSE, CDI, Risk, Food allergy, Cell, Office of the Assistant Secretary for Preparedness and Response, Research, LBP, PureTech Health, Safety, Data analysis, Clostridioides difficile infection, Department, Pharmaceutical industry, Medical device, Antibiotics, VE303, Vedanta Biosciences, VE303, VEDANTA BIOSCIENCES

We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.

Key Points: 
  • We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large.
  • Recurrent CDI causes approximately half a million infections each year in the United States, including up to 165,000 recurring infections and up to 45,000 deaths.
  • Based on the Phase 2 data, BARDA has exercised its first contract option for additional funding of $23.8 million pursuant to its existing 2020 contract with Vedanta.
  • Total committed funding under the BARDA award to date is $31.2 million, inclusive of this first contract option.

PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan

Retrieved on: 
수요일, 9월 29, 2021
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Autism spectrum, Food, Tinnitus, Clinical trial, Language, Infection, Cancer, Partnership, Somnolence, Patient, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, University Challenge 2013–14, Health, Axis, Culture, FDA, Frustration, Population, ASD, Nausea, PureTech Health, Irritability, Biology, Marketing, Environment, Twitter, PRTC, PMDA, Attention deficit hyperactivity disorder predominantly inattentive, Medicine, Company, Government budget balance, Degenerative disease, LSE, U.S. FDA, Disease, Technology, QOL, TAU, Research, BIG, Brain, Variable, Safety, Shionogi, Sham, Pharmaceutical industry, Medical device, Shionogi, Akili, PureTech Health, SHIONOGI, AKILI, PURETECH HEALTH

Based on these results, Shionogi plans to advance SDT-001 into consultation with the Japanese regulatory authority PMDA regarding Phase 3 implementation.

Key Points: 
  • Based on these results, Shionogi plans to advance SDT-001 into consultation with the Japanese regulatory authority PMDA regarding Phase 3 implementation.
  • Shionogi has exclusive rights to the clinical development and is responsible for regulatory filings, sales and marketing of the technologies in Japan and Taiwan.
  • Akili will maintain exclusive global rights to develop and commercialize AKL-T01 and AKL-T02 in all territories outside of Japan and Taiwan.
  • Based on these results, Shionogi plans to advance SDT-001 into consultation with the Japanese regulatory authority PMDA regarding Phase 3 implementation.

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance

Retrieved on: 
월요일, 9월 20, 2021
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Pharmacy, Clinical trial, Cancer, University of Melbourne, Animal, Risk, Axis, Therapy, Abdomen, Celecoxib, FDA, Multimedia, Diabetes, Monash University, Platform supply vessel, Adipose tissue, Glyph, Biomarker, PureTech Health, Monash Institute of Medical Research, Immune system, Biology, Environment, PRTC, Degenerative disease, Company, MIPS, LSE, U.S. FDA, Associate, Technology, Human, Weight gain, Lists of diseases, Research, Obesity, Tissue (biology), Lymphatic system, Brain, BIG, Insulin resistance, Lipid, Plasma, Pharmaceutical industry, the Glyph™ Technology Platform, PureTech Health, THE GLYPH™ TECHNOLOGY PLATFORM, PURETECH HEALTH

View the full release here: https://www.businesswire.com/news/home/20210920005650/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210920005650/en/
    PureTech Health today announced the publication of a research paper in Nature Metabolism using its Glyph technology platform that showed - for the first time - that mesenteric lymphatic dysfunction may be a potential cause of and therapeutic target for obesity and insulin resistance.
  • (Graphic: Business Wire)
    The work demonstrates that obesity may be associated with profound and progressive dysfunction of the mesenteric lymphatic system.
  • As shown in preclinical models, a high-fat diet stimulated the formation of new lymphatic vessels, which grew in a highly disorganized pattern.
  • Results from ex vivo experiments using clinical samples suggest that these observations may extend to humans as well.

PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Retrieved on: 
화요일, 9월 14, 2021
Biotechnology, General Health, Health, Clinical Trials, Oncology, Risk, Cancer, Biology, Medtech, BIG, PureTech Health, FDA, LSE, PRTC, U.S. FDA, Company, Degenerative disease, Axis, Therapy, Environment, Multimedia, Brain, Research, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021 at 4:35 PM EDT.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., Chief Financial Officer, will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021 at 4:35 PM EDT.
  • View the full release here: https://www.businesswire.com/news/home/20210914005224/en/
    PureTech's Chief Financial Officer, George Farmer, Ph.D., will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 4:35pm EDT.
  • This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies.
  • These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future.

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

Retrieved on: 
금요일, 9월 10, 2021
Research, Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Vor Biopharma, PureTech Health, VOR BIOPHARMA, PURETECH HEALTH

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (Vor) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, Vors lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (Vor) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, Vors lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Vor remains on track to report VOR33s initial clinical data in the first half of 2022.
  • The full text of the announcement from Vor is as follows:
    CAMBRIDGE, Mass., Sept. 09, 2021 Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VOR33, the Companys lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for the treatment of acute myeloid leukemia (AML).
  • Therapeutic candidates receiving Fast Track designation may be eligible for priority review and accelerated approval if certain conditions are met.

PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021

Retrieved on: 
월요일, 8월 23, 2021
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Lymphedema, Company, Cancer, Pharmacology, Twitter, Fibrosis, Therapy, PureTech Health, Interstitial lung disease, LSE, PK, Innovation, Fed, IPF, Research, Doctor of Philosophy, Breast cancer–related regulator of tp53, Degenerative disease, Fasting, Inflammation, Biology, Multimedia, Risk, Plasma, Safety, Patient, Environment, Idiopathic pulmonary fibrosis, PRTC, Long COVID, FDA, GI, Brain, Annual report, BIG, Axis, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20210823005064/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210823005064/en/
    PureTech Health today announced the presentation of the Phase 1 multiple ascending dose and food effect study of LYT-100 at the virtual European Respiratory Society International Congress.
  • The Phase 1 multiple ascending dose food and effect study was a randomized, double-blind, placebo-controlled study of LYT-100 in healthy volunteers in both fed and fasting states.
  • PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested.
  • PureTech has also initiated three additional Phase 1 clinical trials to explore further the PK, dosing and tolerability of LYT-100 in healthy volunteers.

PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments

Retrieved on: 
화요일, 8월 17, 2021
Entertainment, Health, FDA, Other Health, Clinical Trials, Electronic Games, Biotechnology, Cancer, Company, Behavior, Axis, Government budget balance, Twitter, Medicine, Australian Securities Exchange, Therapy, Tali, Digital, PureTech Health, PDT Standard, LSE, Leadership, Attention deficit hyperactivity disorder predominantly inattentive, Research, TD1, Food, Doctor of Philosophy, Degenerative disease, Biology, ADHD, Variable, Multimedia, Risk, ASX, Food and Drug Administration, Cognitive neuroscience, Patient, Solution, Environment, CEO, PRTC, FDA, Brain, Annual report, Neuroscience, BIG, Technology, Pharmaceutical industry, Toy

Through this agreement, Akili expects to expand its leadership in prescription digital therapeutics (PDTs) for cognitive impairments and chart a path for a new patient demographic to benefit from innovative technologies proven to improve attention.

Key Points: 
  • Through this agreement, Akili expects to expand its leadership in prescription digital therapeutics (PDTs) for cognitive impairments and chart a path for a new patient demographic to benefit from innovative technologies proven to improve attention.
  • Through this agreement, Akili is expanding its leadership in prescription digital therapeutics (PDTs) for cognitive impairments and charting a path for a new patient demographic to benefit from innovative technologies proven to improve attention.
  • TALi [TALi Digital Limited (ASX: TD1)] is an Australian digital health company delivering diagnostic and therapeutic solutions for cognitive function and behavior.
  • Akili is pioneering the development of digital treatments and care solutions to help people affected by cognitive impairments.

PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer

Retrieved on: 
금요일, 8월 13, 2021
Biotechnology, FDA, Health, Clinical Trials, Biology, Time, Multimedia, Carlo Covi, Johns Hopkins School of Medicine, BIG, CMC, Environment, Endocrinology, Vertex Pharmaceuticals, PureTech Health, Company, Idiopathic pulmonary fibrosis, Cancer, Brain, Twitter, Therapy, Alpert Medical School, Research, LSE, AMAG, FDA, Annual report, Patient, Pharmacovigilance, Leadership, PRTC, AMAG Pharmaceuticals, MedStar Georgetown University Hospital, Axis, Risk, Degenerative disease, Epidemiology, Takeda Oncology, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the appointment of Julie Krop, M.D., as Chief Medical Officer.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (PureTech or the Company), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the appointment of Julie Krop, M.D., as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20210813005024/en/
    PureTech today announced the appointment of Julie Krop, M.D., as Chief Medical Officer.
  • (Photo: Business Wire)
    "We are pleased to welcome Julie to our senior leadership team as our Wholly Owned Pipeline rapidly grows and advances across multiple areas of significant patient need," said Daphne Zohar, Founder and Chief Executive Officer of PureTech.
  • Dr. Krop joins PureTech from Freeline Therapeutics, a clinical-stage gene therapy company, where she served as Chief Medical Officer.